ICH E6(R3) GCP Annex 2
On June 3, 2026, the final ICH E6(R3) Good Clinical Practice Annex 2 was adopted and officially published by the International Council for Harmonisation.
With Annex 1 already moving into implementation, Annex 2 completes the updated global GCP framework. And for biotech and emerging biopharma, this is a signal that the operating model for clinical research must evolve.
Annex 2 brings decentralized, pragmatic, and real-world data clinical trials more explicitly into the GCP conversation. These approaches, once occasional exceptions or innovation pilots at the edge of development, are now increasingly part of how sponsors seek to improve access, reduce patient burden, generate evidence efficiently, and answer clinically meaningful questions.
But the key message Annex 2 brings forward is about how we must govern these trials with rigor and intentionality.
A trial does not become simpler because visits occur remotely, data originate outside the traditional research site, or evidence is generated through routine care. In many ways, it becomes more complex. The data journey is longer. The service provider ecosystem is broader. The handoffs are more numerous. Accountability can become blurred quickly if it is not designed into the program from the start.
For biotech and emerging biopharma organizations, this is where the work becomes very practical.
Before launching a study that uses decentralized elements, pragmatic methods, or RWD, sponsors should be asking these questions:
What are the critical-to-quality factors that truly determine participant protection and the reliability of our results?
Is the protocol feasible for patients, sites, and the operating model we have designed?
Do we have clear decision rights and governance across the sponsor, CRO, technology providers, laboratories, and other partners?
Can we demonstrate oversight of data that move across multiple systems, settings, and owners?
Is the real-world data fit for the development decision it is intended to support?
Are we selecting service providers because they offer an impressive technology platform, or because they can operate within a transparent and accountable governance model?
This is where ICH E6(R3) becomes something special: a leadership framework.
The strongest organizations will use this moment to examine how decisions are made, how risks are surfaced and managed, how vendors are governed, and whether their clinical operating model is truly fit for the studies they intend to run.
Near-global implementation of R3, together with Annex 1 and now Annex 2, raises the bar for everyone involved in clinical development. Innovation in trial design must be matched by disciplined governance, purposeful oversight, and a clear understanding of where accountability resides.
For biotech and emerging biopharma, that can feel daunting. But it is also an opportunity.
Organizations that build quality into design early and establish strong governance before their trials become operationally complex will be better positioned to move quickly without losing control.
If you’re ready to translate GCP innovation into practical governance and operational control, let’s connect!
Decentralized and real-world designs change what oversight has to reach. Some of the recurring questions are answered in the FAQ on E6(R3) and vendor governance.
